Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

被引：27

作者：

Zhao, Wan-Hong ^{[1
]}

Liu, Jie ^{[1
]}

Wang, Bai-Yan ^{[1
]}

Chen, Yin-Xia ^{[1
]}

Cao, Xing-Mei ^{[1
]}

Yang, Yun ^{[1
]}

Zhang, Yi-Lin ^{[1
]}

Wang, Fang-Xia ^{[2
]}

Zhang, Peng-Yu ^{[1
]}

Lei, Bo ^{[1
]}

Gu, Liu-Fang ^{[1
]}

Wang, Jian-Li ^{[1
]}

Yang, Nan ^{[1
]}

Zhang, Ru ^{[1
]}

Zhang, Hui ^{[1
]}

Shen, Ying ^{[1
]}

Bai, Ju ^{[1
]}

Xu, Yan ^{[1
]}

Wang, Xu-Geng ^{[1
]}

Zhang, Rui-Li ^{[1
]}

Wei, Li-Li ^{[1
]}

Li, Zong-Fang ^{[3
]}

Li, Zhen-Zhen ^{[3
]}

Geng, Yan ^{[4
]}

He, Qian ^{[4
]}

Zhuang, Qiu-Chuan ^{[5
]}

Fan, Frank Xiao-Hu ^{[5
]}

He, Ai-Li ^{[1
,3
]}

Zhang, Wang-Gang ^{[1
]}

机构：

[1] Xi An Jiao Tong Univ, Dept Hematol, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[3] Xi An Jiao Tong Univ, Natl Local Joint Engn Res Ctr Biodiagnost & Bioth, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[4] Xi An Jiao Tong Univ, Dept Clin Lab, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[5] Nanjing Legend Biotech, Nanjing, Jiangsu, Peoples R China

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-110548

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

955

引用

页数：4

共 50 条

[1] A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao
Jie Liu
Bai-Yan Wang
Yin-Xia Chen
Xing-Mei Cao
Yun Yang
Yi-Lin Zhang
Fang-Xia Wang
Peng-Yu Zhang
Bo Lei
Liu-Fang Gu
Jian-Li Wang
Nan Yang
Ru Zhang
Hui Zhang
Ying Shen
Ju Bai
Yan Xu
Xu-Geng Wang
Rui-Li Zhang
Li-Li Wei
Zong-Fang Li
Zhen-Zhen Li
Yan Geng
Qian He
Qiu-Chuan Zhuang
Xiao-Hu Fan
Ai-Li He
Wang-Gang Zhang
Journal of Hematology & Oncology, 11
[2] A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Zhao, Wan-Hong
Liu, Jie
Wang, Bai-Yan
Chen, Yin-Xia
Cao, Xing-Mei
Yang, Yun
Zhang, Yi-Lin
Wang, Fang-Xia
Zhang, Peng-Yu
Lei, Bo
Gu, Liu-Fang
Wang, Jian-Li
Yang, Nan
Zhang, Ru
Zhang, Hui
Shen, Ying
Xu, Ju Bai Yan
Wang, Xu-Geng
Zhang, Rui-Li
Wei, Li-Li
Li, Zong-Fang
Li, Zhen-Zhen
Geng, Yan
He, Qian
Zhuang, Qiu-Chuan
Fan, Xiao-Hu
He, Ai-Li
Zhang, Wang-Gang
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[3] Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR- T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma)
Chen, Lijuan
Xu, Jie
Fu, Weijun
Jin, Shiwei
Yang, Shuangshuang
Yan, Sun
Wu, Wen
Liu, Yuanfang
Zhang, Wu
Weng, Xiangqin
Wang, Yan
Wang, Jin
Ding, Xiaoyi
Li, Biao
Zhu, Jiang
Chen, Zhu
Fan, Frank Xiao-Hu
Li, Jianyong
Hou, Jian
Chen, Sai-Juan
Mi, Jian-Qing
BLOOD, 2019, 134
[4] Long-Term Follow-up of a Phase 1, Firstin-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Wang, Bai-Yan
Zhao, Wan-Hong
Liu, Jie
Chen, Yin-Xia
Cao, Xing-Mei
Yang, Yun
Zhang, Yi-Lin
Wang, Fang-Xia
Zhang, Peng-Yu
Lei, Bo
Gu, Liu-Fang
Wang, Jian-Li
Zhang, Jia-Jia
Zhang, Ru
Zhang, Hui
Shen, Ying
Bai, Ju
Xu, Yan
Wang, Xu-Geng
Zhang, Rui-Li
Wei, Li-Li
Li, Zong-Fang
He, Gai-Xia
Geng, Yan
He, Qian
Zhuang, Qiu-Chuan
Fan, Frank Xiao-Hu
Zhang, Wang-Gang
He, Ai-Li
BLOOD, 2019, 134
[5] Preclinical assessment of LCAR-B38M, a novel BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory multiple myeloma
Fan, Xiaohu
Zhuang, Qiuchuan
Yang, Lei
Hao, Jiaying
Zhao, Dan
Zhao, Yuncheng
Wang, Pingyan
Geng, Dong
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E160 - E160
[6] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Berdeja, Jesus G.
Madduri, Deepu
Usmani, Saad Z.
Jakubowiak, Andrzej
Agha, Mounzer
Cohen, Adam D.
Stewart, A. Keith
Hari, Parameswaran
Htut, Myo
Lesokhin, Alexander
Deol, Abhinav
Munshi, Nikhil C.
O'Donnell, Elizabeth
Avigan, David
Singh, Indrajeet
Zudaire, Enrique
Yeh, Tzu-Min
Allred, Alicia J.
Olyslager, Yunsi
Banerjee, Arnob
Jackson, Carolyn C.
Goldberg, Jenna D.
Schecter, Jordan M.
Deraedt, William
Zhuang, Sen Hong
Infante, Jeffrey
Geng, Dong
Wu, Xiaoling
Carrasco-Alfonso, Marlene J.
Akram, Muhammad
Hossain, Farah
Rizvi, Syed
Fan, Frank
Lin, Yi
Martin, Thomas
Jagannath, Sundar
LANCET, 2021, 398 (10297): : 314 - 324
[7] CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
Madduri, Deepu
Berdeja, Jesus G.
Usmani, Saad Z.
Jakubowiak, Andrzej
Agha, Mounzer
Cohen, Adam D.
Stewart, A. Keith
Hari, Parameswaran
Htut, Myo
O'Donnell, Elizabeth
Munshi, Nikhil C.
Avigan, David E.
Deol, Abhinav
Lesokhin, Alexander M.
Singh, Indrajeet
Zudaire, Enrique
Yeh, Tzu-Min
Allred, Alicia J.
Olyslager, Yunsi
Banerjee, Arnob
Goldberg, Jenna D.
Schecter, Jordan M.
Jackson, Carolyn C.
Deraedt, William
Zhuang, Sen Hong
Infante, Jeffrey R.
Geng, Dong
Wu, Xiaoling
Carrasco, Marlene J.
Akram, Muhammad
Hossain, Farah
Rizvi, Syed
Fan, Frank
Jagannath, Sundar
Lin, Yi
Martin, Thomas, III
BLOOD, 2020, 136
[8] Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
Mi, Jian-Qing
Zhao, Wanhong
Jing, Hongmei
Fu, Weijun
Hu, Jianda
Chen, Lijuan
Zhang, Yiwen
Yao, Dan
Chen, Diana
Schecter, Jordan M.
Yang, Fan
Tian, Xiaochen
Sun, Huabin
Zhuang, Sen Hong
Ren, Jimmy
Fan, Xiaohu
Jin, Jie
Niu, Ting
Chen, Sai-Juan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1275 - +
[9] Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study (vol 398, pg 314, 2021)
Berdeja, J. G.
Madduri, D.
Usmani, S. Z.
LANCET, 2021, 398 (10307): : 1216 - 1216
[10] Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM)
Jagannath, Sundar
Berdeja, Jesus G.
Jakubowiak, Andrzej
Agha, Mounzer
Cohen, Adam
Madduri, Deepu
Hari, Parameswaran
Yeh, Tzu-Min
Olyslager, Yunsi
Banerjee, Arnob
Jackson, Carolyn C.
Allred, Alicia
Zudaire, Enrique
Deraedt, William
Wu, Xiaoling
Pacaud, Lida
Akram, Muhammad
Lin, Yi
Martin, Thomas
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S15 - S16

← 1 2 3 4 5 →